Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?

Tempus AI (TEM) anticipates positive adjusted EBITDA of $5 million for 2025, a $110 million improvement over 2024, driven by a 75.4% increase in first-quarter revenue and a 99.8% surge in gross profit. The company narrowed its Q1 adjusted EBITDA loss by $27.8 million year-over-year, signaling disciplined cost management and operating leverage, while peers like Guardant Health and Myriad Genetics show mixed results. Tempus AI shares have climbed 71.8% year-to-date, significantly outpacing the industry's 22.9% growth, though the stock holds a Zacks Rank #4 (Sell).

Analysis

Tempus AI (TEM) is demonstrating significant operational momentum, reporting a 75.4% year-over-year revenue increase in its first quarter of 2025, primarily driven by an 89% growth in Genomics and a $63.5 million contribution from Hereditary testing. More impressively, its gross profit surged 99.8% year-over-year, nearly doubling the growth rate of Q4 2024, fueled by gross margin expansion in both Genomics and Data & services product lines. This robust top-line and margin improvement, coupled with disciplined cost management, led to a $27.8 million reduction in its first-quarter adjusted EBITDA loss to negative $16.2 million. Critically, Tempus AI has guided for a positive full-year adjusted EBITDA of $5 million in 2025, an approximate $110 million improvement over 2024, signaling a pivotal shift towards profitability. This performance contrasts favorably with peers like Guardant Health, which reported a Q1 2025 adjusted EBITDA loss of $58.5 million, and Myriad Genetics, which, despite nearing breakeven adjusted EBITDA, experienced declining revenues. Despite Tempus AI's strong operational performance and a 71.8% year-to-date stock appreciation that significantly outpaces the industry’s 22.9% growth, the stock trades at a forward 12-month sales multiple of 7.36X, which is above the industry average of 6.03X, though below its own historical median. However, cautionary signals include a Zacks Rank #4 (Sell), a Value Score of F, and mixed Zacks Consensus Estimates for its 2025 and 2026 earnings, suggesting potential investor skepticism or uncaptured risks despite the operational advancements. The company's stated strategy to reinvest potential EBITDA beats into growth initiatives, such as technology and personnel, further underscores a long-term focus over immediate profit maximization.

Key Decisions for Investors

• Investors should acknowledge Tempus AI's strong revenue growth, significant gross profit acceleration, and clear guidance towards achieving positive adjusted EBITDA in 2025, which are key positive catalysts.
• Consider the substantial 71.8% year-to-date stock price increase and evaluate the current valuation, with a forward sales multiple of 7.36X, in the context of its growth prospects, industry comparison, and its own historical valuation levels.
• Carefully weigh the company's impressive operational achievements and strategic reinvestment for long-term growth against potentially conflicting indicators such as its Zacks Rank #4 (Sell), a Value Score of F, and mixed analyst earnings estimates for the coming years.